Reference Interval:
Effective February 19, 2013
| Age
| Male
| Female
| | 0-13 days
| 5,000-105,000 ng/mL
| 5,000-105,000 ng/mL
| | 14-30 days
| 300-60,000 ng/mL
| 300-60,000 ng/mL
| | 1 month
| 100-10,000 ng/mL
| 100-10,000 ng/mL
| | 2 months
| 40-1,000 ng/mL
| 40-1,000 ng/mL
| | 3 months
| 11-300 ng/mL
| 11-300 ng/mL
| | 4 months
| 5-200 ng/mL
| 5-200 ng/mL
| | 5 months
| 0-90 ng/mL
| 0-90 ng/mL
| | 6-11 months
| 0-90 ng/mL
| 0-99 ng/mL
| | 1 year
| 0-19 ng/mL
| 0-36 ng/mL
| | 2 years
| 0-12 ng/mL
| 0-12 ng/mL
| | 3-6 years
| 0-5 ng/mL
| 0-5 ng/mL
| | 7 years and older
| 0-9 ng/mL
| 0-9 ng/mL
|
|
| Interpretive Data: |
The Beckman Coulter Access DxI AFP method is used. Results obtained with different assay methods or kits cannot be used interchangeably. AFP is a valuable aid in the management of nonseminomatous testicular cancer patients when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased AFP concentrations have also been observed in ataxia telangiectasia, hereditary tyrosinemia, primary hepatocellular carcinoma, teratocarcinoma, gastrointestinal tract cancers with and without liver metastases, and in benign hepatic conditions such as acute viral hepatitis, chronic active hepatitis, and cirrhosis. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable as a tumor marker in pregnant females.
|
| Note: |
Adult males and nonpregnant females: 0.0-9.0 ng/mL
|
| CPT Code(s): |
82105
|
Cross References: |
AFP (Alpha Fetoprotein, Serum (Tumor Marker)) |
|
